Belarusian Research Center for Pediatric Oncology, Hematology and Immunology
6
3
3
1
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 6 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 1 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (6)
Immunotherapy With ex Vivo Expanded Haploidentical Natural Killer Cells for Children/Young Adults With AML
Role: lead
Pilot CAR-T Cells Therapy for Children/Young Adults With CD19+ R/R Leukemia/Lymphoma
Role: lead
Expanded Haploidentical Natural Killer Cells as Consolidation Strategy for Children/Young Adults With AML
Role: lead
Assesment of the Functional Activity of Platelets for the Differential Diagnosis of Thrombocytopathies
Role: collaborator
Safety of Expanded Haploidentical Natural Killer Cells for Leukemia
Role: lead
DNA Vaccination Against Neuroblastoma
Role: lead
All 6 trials loaded